Table 2 ProET-1 values and different cut-offs stratified by the analyzed respiratory infections and by survivors and non-survivors
|  | Pneumonia (n = 876) | Acute or chronic exacerbated bronchitis (n = 371) | SARS-CoV-2 (n = 74) | |||
|---|---|---|---|---|---|---|
Survivors (n = 827) | Non-Survivors n = 49) | Survivors (n = 361) | Non-Survivors (n = 10) | Survivors (n = 57) | Non-Survivors (n = 17) | |
proET-1 values | ||||||
 proET-1 overall [pmol/L], median (IQR) | 110.0 (80.0, 163.0) | 209.0 (135.0, 328.0) | 94.0 (67.0, 133.0) | 176.5 (155.0, 230.0) | 53.6 (37.0, 69.0) | 81.8 (76.0, 118.0) |
proET-1 cut-offs, n (%) | ||||||
 < 74 [pmol/L] | 162 (19.6%) | 3 (6%) | 114 (31.6%) | 0 (0%) | 44 (77.2%) | 4 (24%) |
  ≥ 74 [pmol/L] | 141 (17.0%) | 4 (8%) | 68 (18.8%) | 1 (10%) | 8 (14.0%) | 8 (47%) |
  > 94 [pmol/L] | 292 (35.3%) | 9 (18%) | 115 (31.9%) | 1 (10%) | 3 (5.3%) | 3 (18%) |
  > 154 [pmol/L] | 232 (28.1%) | 33 (67%) | 64 (17.7%) | 8 (80%) | 2 (3.5%) | 2 (12%) |
proET-1 median-cut-off, n, (%) | ||||||
  < 107 [pmol/L] | 378 (45.7%) | 9 (18%) | 215 (59.6%) | 1 (10%) | 52 (91.2%) | 12 (71%) |
  ≥ 107 [pmol/L] | 449 (54.3%) | 40 (82%) | 146 (40.4%) | 9 (90%) | 5 (8.8%) | 5 (29%) |